Replimune Group Inc. (REPL)
NASDAQ: REPL
· Real-Time Price · USD
5.86
-0.15 (-2.50%)
At close: Sep 12, 2025, 12:22 PM
-2.50% (1D)
| Bid | 5.85 |
| Market Cap | 457.41M |
| Revenue (ttm) | 1.47M |
| Net Income (ttm) | -280.22M |
| EPS (ttm) | -3.24 |
| PE Ratio (ttm) | -1.81 |
| Forward PE | -2.01 |
| Analyst | Hold |
| Ask | 7.53 |
| Volume | 402,041 |
| Avg. Volume (20D) | 9,221,301 |
| Open | 5.96 |
| Previous Close | 6.01 |
| Day's Range | 5.84 - 6.00 |
| 52-Week Range | 2.68 - 17.00 |
| Beta | 0.51 |
About REPL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol REPL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for REPL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Replimune Group Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+10.68%
Replimune shares are trading higher, reversing aft...
Unlock content with
Pro Subscription
1 month ago
+101.33%
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
